Table 4.
Summary of reasons for pembrolizumab discontinuation: Spotlight cohort.
| Spotlight (n = 228) | |
|---|---|
| Discontinued, n (%) | 151 (66.2) |
| Reasons for discontinuation, n (%) | N=151 a |
| Progression | 70 (46.4) |
| Adverse effect of therapy | 35 (23.2) |
| Disease-related symptoms not due to therapy | 23 (15.2) |
| Patient request | 6 (4) |
| Completed treatment | 5 (3.3) |
| No evidence of disease | 2 (1.3) |
| Other b | 13 (8.6) |
| Unknown | 1 (0.7) |
a
Patients could have more than one reason for discontinuation.
b
For patients with ongoing treatment until the time of death, the reason recorded was “Other” to comply with data deidentification requirements.